In clinical observational studies, diverse serum inflammatory markers such as C-reactive protein (CRP), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) turned out to be significantly related with clinical outcomes in patients with NSCLC, irrespective of the tumor stage and treatment modalities [6,7,8]. The gene discussed is CRP; the disease is non-small cell lung carcinoma.